Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA-CART-STriKE + IL-15 + anti-FAP + anti-CD16
- Development stage
- Preclinical
- Lead developer
- Mayo Clinic
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
BCMA-CART-STriKE + IL-15 + anti-FAP + anti-CD16 is an experimental chimeric antigen receptor (CAR) T-cell therapy designed to treat multiple myeloma by targeting both the tumor cells and the immunosuppressive bone marrow microenvironment. Developed at the Mayo Clinic, this construct utilizes the "STriKE" (Secreted Tri-specific Killer Engager) platform, where BCMA-targeted CAR-T cells are engineered to secrete a tri-specific molecule composed of interleukin-15 (IL-15), an anti-fibroblast activation protein (FAP) moiety, and an anti-CD16 moiety. The BCMA CAR-T component directly targets and eliminates B-cell maturation antigen-expressing myeloma cells. Simultaneously, the secreted tri-specific molecule targets FAP-positive inhibitory cancer-associated fibroblasts (iCAFs) and recruits/activates CD16-positive innate immune cells (such as NK cells and macrophages) via IL-15 and CD16 binding to eliminate these fibroblasts. This dual approach aims to overcome resistance mediated by the tumor microenvironment and enhance the persistence and efficacy of the CAR-T therapy.
- Other names
- BCMA-CART-STriKE (IL-15/anti-FAP/anti-CD16)
02
Targets
BCMA (B-cell maturation antigen)FCGR3B (Fc gamma receptor III)FAP (Fibroblast activation protein alpha)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on BCMA-CART-STriKE + IL-15 + anti-FAP + anti-CD16.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA-CART-STriKE + IL-15 + anti-FAP + anti-CD16.